Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Novartis : INTENT TO SOLE source

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 06:03pm CEST

Notice Type: CONTRACT AWARD

Posted Date: 03-OCT-17

Office: Bureau of Medicine and Surgery

Location: NAVAL MEDICAL CENTER SAN DIEGO

Office Address: DEPARTMENT OF THE NAVY, BUREAU OF MEDICINE AND SURGERY, NAVAL MEDICAL CENTER SAN DIEGO, BLDG 134800 BOB WILSON DRIVE SAN DIEGO, CA 92134-5000

Classification Code: Q - Medical services

Subject: INTENT TO SOLE source

Solicitation Number: N0025917N0100

Award Number: N0025917P0670

Award Date: 082817

Awardee: ALCON LABORATORIES, INC.

Archive: 10042017

Contact: ARATIYA K. LUSK, EMAIL [email protected]

Internet Link: https://www.fbo.gov/spg/DON/BUMED/N00259/Awards/N0025917P0670.html

Copyright (c) 2017 Federal Information & News Dispatch, Inc., source Federal Documents

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
10/13 NOVARTIS : Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoretinal ..
10/13 NOVARTIS : 65-- Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoret..
10/13 NOVARTIS AG (ADR)(NYSE : NVS) Says It Will Not Sell Its Stake In Roche
10/13 NOVARTIS : Alcon Centurion Analyzers (Optometry) | 10/1/17 - 093018 ultimate end..
10/12 NOVARTIS : Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Tri..
10/11 NOVARTIS : Alcon Centurion Analyzers (Optometry) | 10/1/17 - 093018 ultimate end..
10/11 NOVARTIS : J-- Alcon Centurion Analyzers (Optometry) | 10/1/17 - 093018 ultimate..
10/11 NOVARTIS : Foundation launches Healthy Schools for Healthy Communities with the ..
10/11 NOVARTIS : Foundation launches Healthy Schools for Healthy Communities with the ..
10/10 NOVARTIS : Alcon receives CE Mark for first of its kind AutonoMe preloaded intra..
More news
News from SeekingAlpha
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 SANOFI : Upward Trajectory In 2017
10/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 14, 2017
10/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 13, 2017
10/11 Hurricane-related damage could cause shortages of 40 drugs - FDA
Financials ($)
Sales 2017 48 768 M
EBIT 2017 11 713 M
Net income 2017 7 272 M
Debt 2017 17 716 M
Yield 2017 3,29%
P/E ratio 2017 25,59
P/E ratio 2018 21,86
EV / Sales 2017 5,02x
EV / Sales 2018 4,79x
Capitalization 227 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 0,92%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.23%226 956
JOHNSON & JOHNSON18.42%366 178
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887
AMGEN25.17%133 538